Hengrui SHR6390 intends to be included in the breakthrough therapy CDK4/6 inhibitor mixture…

On March 5, 2021 Hengrui Pharmaceutical’s reported its innovative drug SHR6390 tablets was included in the list of proposed breakthrough treatments by the Drug Evaluation Center of the National Medical Products Administration (Press release, Hengrui Pharmaceuticals, MAR 5, 2021, View Source [SID1234633503]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Source: CDE
SHR6390 is an oral, high-efficiency and selective small molecule CDK4/6 inhibitor developed by Jiangsu Hengrui, which belongs to the first class of chemical drugs.

Introduction to CDK4/6 Inhibitors
Introduction to CDK4/6 Inhibitors
Cyclin Dependent Kinase (CDK) is a key kinase involved in cell cycle regulation.

CDK4/6 inhibitor approval status

CDK4/6 inhibitor approval status
In recent years, CDK4/6 inhibitors are rapidly changing the treatment pattern of HR+ and HER2- advanced breast cancer.

Pfizer’s piperacillil no longer leads the way, CDK4/6 inhibitor melee is about to start
Pfizer’s piperacillil no longer leads the way, CDK4/6 inhibitor melee is about to start
As the first CDK4/6 inhibitor drug to be marketed, Pfizer’s piperacillil has an obvious first-mover advantage.

It can be said that piperacillil dominates the CDK4/6 inhibitor market, and even if reboxilil and abecilil are listed afterwards, they have not been able to shake its market position.

In fact, on December 18, 2020, Qilu Pharmaceutical’s 4 generic drugs, piperacillil capsules, have been approved for marketing by NMPA, which is the first imitation of this variety, and its indication is the first-line combination of aromatase inhibitors to treat postmenopausal patients.

(Source: CDE)

In short, CDK 4/6 is a star target, and many companies are developing innovative drugs in the country.

Reference source:

Reference source:
1.

3.

4.
Im SA, Lu YS, Bardia A, et al.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med.
2019;381(4):307-316.